Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 134

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 134
---
 well as ownership and investment interests held by the physicians 
 described above and their immediate family members;                                                                                                                                                                                                     |

| • |     | federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and 
 activities that potentially harm consumers;                                                                |

| • |     | the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical 
 devices;                                                                                                       |

| • |     | federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing                                                                                                                                    
 metrics to government agencies, including CMS and Department of Veterans Affairs (“VA”), referred to as Government Program Statutory Price Reporting, where such reported prices are used in the calculation of reimbursement and/or discounts       
 on marketed products paid by government healthcare programs. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal      
 healthcare programs and increased infrastructure costs, and may potentially limit a drug manufacturer’s ability to offer certain marketplace discounts. Additionally, if it is determined by the government, which could include a government agency 
 such as CMS, Health Resources and Services Administration (“HRSA”), the VA, or by the Office of Inspector General or Department of Justice, that the Statutory Price Reporting was incorrect, causing the government to essentially pay more         
 than they should through the reimbursement and/or discount, the manufacturer may be subject to significant False Claims Act investigations, civil monetary penalties and/or additional fines;                                                        |

| • |     | the Prescription Drug Marketing Act, which restricts the manner in which manufacturers may disseminate                                                             
 complimentary drug samples to healthcare practitioners, requires physical and accounting controls, and establishes penalties for improper sample distribution; and |

| • |     | state law equivalents of each of the above federal laws, such as licensing, anti-kickback, false claims, consumer                                                                                                                                        
 protection and unfair competition laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s            
 voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug 
 manufacturers to file reports with states regarding pricing information and marketing expenditures, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and        
 entities, and state laws governing the privacy and security of health information in certain circumstances,